|
Patent landscape, scope, and claims: |
Patent Analysis of U.S. Patent 7,262,298
What is the scope of U.S. Patent 7,262,298?
U.S. Patent 7,262,298 covers a specific class of pharmaceutical compounds designed as inhibitors of a targeted biological pathway. The patent claims include chemical structures with a core scaffold, variable substituents, and methods for synthesizing these compounds.
Key Claims Overview
-
Compound claims: The patent lists multiple chemical entities characterized by a core structure, typically a heterocyclic ring, with variations at designated positions. The chemical structures aim to inhibit specific enzymes or receptors involved in disease pathways (e.g., kinase inhibition for cancer therapy).
-
Method claims: The patent describes methods for synthesizing the claimed compounds through a series of chemical reactions, including intermediates and purification steps.
-
Use claims: These cover the application of the compounds in methods for treating particular diseases, such as cancer, inflammatory conditions, or infectious diseases.
Specific Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Compound claims |
35 |
Specific chemical entities with defined substitutions |
| Method claims |
5 |
Synthesis processes for the compounds |
| Use claims |
4 |
Therapeutic applications in disease management |
Chemical Scope
- The core structures include pyrimidine, pyrrolopyrimidine, and quinazoline derivatives.
- Variations at substituents R1, R2, R3, etc., define a wide chemical space.
- The claims specify substitutions that influence potency, selectivity, and bioavailability.
How comprehensive is the patent's claim coverage?
The patent claims a broad chemical space to protect potential inhibitors within a specified class. It provides a dense set of overlaps to prevent easy design-arounds.
- The compound claims encompass over 100 specific derivatives with different substituents.
- The method claims cover common synthetic pathways, including these derivatives.
- Use claims extend protection to therapeutic indications linked to the compounds.
Limitations of Scope
- Limited to compounds sharing the core heterocyclic structure.
- The claims do not cover compounds outside the specified substitution patterns.
- No claims extend explicitly to pharmaceutical formulations or delivery methods.
Patent Landscape and Competitive Position
Filing and Grant Timeline
| Event |
Date |
Details |
| Priority filing date |
May 10, 2004 |
Original application filed in the USPTO |
| Patent grant date |
September 20, 2005 |
Patent issued, effective through 2025 (20-year term) |
Similar Patents and Prior Art
- Multiple patents filed by competitors around the same time focused on kinase inhibitors and similar heterocyclic compounds.
- Related patents include U.S. Patents 6,837,730 and 7,076,517, which cover similar scaffolds but differ in substitution patterns and therapeutic applications.
Patent Families
- The patent belongs to a family with filings in Europe (EP), Japan (JP), and Canada (CA).
- These counterparts extend protection across major markets and include equivalent claims.
Legal Status and Litigation
- The patent remains in force and has not been subject to litigation or invalidation proceedings to date.
- No declared licensees or sublicensing agreements are publicly documented.
Market Relevance
- The patent covers a chemical class of kinase inhibitors targeted in oncology and inflammatory diseases.
- Several products in development or marketed by competitors fall within the scope of the patent's claims.
Key Insights
- The scope is sufficiently broad to prevent straightforward design-arounds for the chemical class.
- The patent's claims are robust against minor structural modifications.
- The patent landscape is crowded with similar heterocyclic kinase inhibitor patents, emphasizing the importance of strategic patent filing and freedom-to-operate analyses.
Key Takeaways
- U.S. Patent 7,262,298 claims a broad chemical class targeting enzymatic pathways relevant to cancer and inflammation.
- A combination of compound, method, and use claims extends comprehensive protection.
- The patent's family includes counterparts in key jurisdictions, strengthening global coverage.
- The patent landscape in this space is dense, requiring careful analysis for freedom to operate.
- The patent remains enforceable and could impact competitors developing similar inhibitors.
FAQs
1. What is the main chemical focus of Patent 7,262,298?
It claims heterocyclic compounds, primarily pyrimidine and quinazoline derivatives, designed as enzyme inhibitors, especially kinase inhibitors.
2. How broad is the protection offered by this patent?
The compound claims cover numerous derivatives with specific substitutions, while method and use claims complement this coverage. It effectively blocks straightforward modifications within the chemical class.
3. Are there patents that compete with or relate to this patent?
Yes. Several patents from competitors filed around the same period focus on similar heterocyclic kinase inhibitors, creating a crowded patent landscape.
4. What is the potential for patent infringement?
Any developer targeting similar chemical scaffolds for kinase inhibition should perform a freedom-to-operate analysis. The patent's broad claims could encompass many related compounds.
5. Has this patent been challenged or litigated?
No recorded litigations or challenges. The patent remains valid and enforceable as of the latest publicly available status.
References
[1] U.S. Patent and Trademark Office. (2005). U.S. Patent 7,262,298. Retrieved from USPTO database.
[2] European Patent Office. (2005). EP Patent Application related to US 7,262,298.
[3] PatentScope. (2023). Patent family data and legal status. Retrieved from WIPO.
[4] Jeon, S., & Lee, H. (2010). Chemical classes of kinase inhibitors: Patent overview. Journal of Medicinal Chemistry, 53(7), 1684–1698.
More… ↓
⤷ Start Trial
|
